Jing Xiao, Danlei Song, Caiming Liang, Yinuo H E, Weifang Zheng, Xiaqiu W U
Department of Biobank, Lanxi Hospital of Traditional Chinese Medicine, Jinhua 321102, China.
Department of Anorectal, Lanxi Hospital of Traditional Chinese Medicine, Jinhua 321102, China.
J Tradit Chin Med. 2025 Apr;45(2):225-233. doi: 10.19852/j.cnki.jtcm.2025.02.008.
To systematically review the efficacy and safety of Jianpi formulas in reducing the recurrence of colorectal adenoma (CRA) after poly-pectomy.
Randomized controlled trials (RCTs) investigating Jianpi formulas for CRA post-polypectomy were systematically retrieved from eight electronic databases. The quality of the methodology was assessed using the Cochrane collaboration tool. The Grades of Recommendations Assessment Development and Evaluation (GRADE) approach was employed for evidence assessment. Statistical analyses were conducted using Statistics and Data Analysis (STATA) 17 (StataCorp (College Station, TX, USA) and Review Manager (RevMan) 5.4 (The Cochrane Collaboration (London, UK).
The Meta-analysis, encompassing 18 RCTs with 1838 patients, revealed that Jianpi formulas significantly outperformed postoperative routine treatment. It demonstrated a reduction in the half-year recurrence rate [relative risk () = 0.41, 95% confidence interval () = 0.33-0.49, = 9.08, 0.000 01], the one-year recurrence rate [ = 0.58, 95% = 0.49-0.69, = 6.12, 0.000 01], and an enhancement in the clinical effective rate [ = 1.27, 95% = 1.19-1.36, = 7.06, 0.000 01]. The half-year recurrence rate and the clinical effective rate were medium-quality evidence. The one-year recurrence rate was low-quality evidence. Additionally, Jianpi formulas appear to be safe and do not increase adverse reactions compared to postoperative routine treatment alone.
Jianpi formulas exhibit efficacy in reducing postoperative half-year and one-year recurrence rates while improving the clinical effective rate after polypectomy for CRA.
系统评价健脾方剂在降低结肠直肠腺瘤(CRA)息肉切除术后复发率方面的疗效和安全性。
从八个电子数据库中系统检索研究健脾方剂用于CRA息肉切除术后的随机对照试验(RCT)。使用Cochrane协作工具评估方法学质量。采用推荐分级评估、制定与评价(GRADE)方法进行证据评估。使用统计分析软件(STATA)17(美国德克萨斯州大学站StataCorp公司)和RevMan 5.4(英国伦敦Cochrane协作网)进行统计分析。
Meta分析纳入18项RCT共1838例患者,结果显示健脾方剂显著优于术后常规治疗。其半年复发率降低[相对危险度(RR)=0.41,95%置信区间(CI)=0.33 - 0.49,Z = 9.08,P < 0.000 01],一年复发率降低[RR = 0.58,95%CI = 0.49 - 0.69,Z = 6.12,P < 0.000 01],临床有效率提高[RR = 1.27,95%CI = 1.19 - 1.36.Z = 7.06,P < 0.000 01]。半年复发率和临床有效率为中等质量证据。一年复发率为低质量证据。此外,与单纯术后常规治疗相比,健脾方剂似乎安全且不会增加不良反应。
健脾方剂在降低CRA息肉切除术后半年和一年复发率以及提高临床有效率方面具有疗效。